Maintenance of normal vitamin D levels during anti-PD-1 immunotherapy should be standard procedure for patients with advanced melanoma to allow for better treatment outcomes, according to a report in Cancer.
Data showed a higher objective response rate and significantly longer median PFS after anti-PD-1 therapy among patients with normal vitamin D levels compared with patients who had low levels and no supplementation.
“I have been working on the topic of the importance of proper vitamin D levels during melanoma immunotherapy for over 4 years,” Łukasz Galus, MD, of the department of